How Will Pharma M&A Change In 2017?
Industry consultants survey the landscape for pharma deal making in 2017. More deals, higher prices and asset swaps as repatriated cash burns holes in US pharma's pockets are just for starters.
Industry consultants survey the landscape for pharma deal making in 2017. More deals, higher prices and asset swaps as repatriated cash burns holes in US pharma's pockets are just for starters.